Winnonlin pro 5

Fimasartan and linagliptin PK analyses were performed using non-compartmental methods with WinNonlin Pro 5.3 (Pharsight Corporation, Mountain View, CA, USA). The area under the plasma concentration–time curve over the dosing interval (τ) after repeated dose administration at steady state (AUC_τ,ss) was calculated using the linear trapezoidal method. The maximum plasma concentration of drug at steady state (C_max,ss) and the time to reach C_max,ss (T_max,ss) were taken directly from the observed plasma concentrations over time. The apparent clearance was calculated by dividing the dose by the AUC_τ,ss.

β-lapachone PK parameters in plasma were determined by non-compartmental methods, using WinNonlin Pro 5.3 software (Pharsight Corporation, Mountain View, CA, USA), based on individual subject β-lapachone plasma concentrations, using actual sampling times after the first or last 100 mg maintenance dose administration. Maximum plasma concentration (C_max), minimum plasma concentration (C_min), and time to reach C_max (t_max) were estimated directly from the observed plasma concentration–time data curve. Terminal elimination rate constant (k_e) was determined by linear regression on the final data points (at least three) of log-linear decline. β-lapachone apparent elimination half-life (t_½) was calculated as 0.693/k_e. The area under the plasma concentration–time curve over the dosing interval after multiple-dose administration (AUC_τ) was calculated using the linear trapezoidal method. All estimated PK parameters were summarized descriptively as mean ± standard deviation (SD) values.

We derived the pharmacokinetic parameters for esomeprazole using actual sampling times with a noncompartmental pharmacokinetic analysis provided by WinNonlin Pro 5.3 (Pharsight Corporation, Mountain View, CA, USA) as follows: the maximum plasma concentration (C_max), the time to reach C_max (T_max), the area under the plasma concentration-time curve (AUC) to the last measurable time (AUC_last), the AUC to infinity (AUC_inf), C_max during a dosing interval (τ) at steady state (C_max,ss); the time to reach C_max,ss (T_max,ss); AUC after repeated dosing at steady state (AUC_τ,ss), and elimination half-life (t_1/2).